The phase III RUBY and NRG-GY018 trials indicate that women with advanced endometrial cancer whose disease is newly diagnosed or has recurred for the first time benefit from the combination of a PD-1 inhibitor with standard chemotherapy. Adding either dostarlimab or pembrolizumab significantly prolonged progression-free survival, with overall survival also trending in the right direction.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.